Skip to main content

Table 2 Antibody concentrations stratified by the clinical classification

From: The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19

  Clinical Classification Sum P value
Mild Regular Severe
N 1 34 6 41
Age 25 52.5 (39.8, 64.8) 67.0 (55.5,71.5) 60.0 (39.5,67.5) 0.091
Male 0.0% 50.0% 33.3% 51.2% 0.366
Concentration of COVID-19 IgG (AU/ml) 9.1 22.2 (3.9, 89.4) 157.9 (28.8190.7) 30.6 (8.4, 129.4) 0.056
Seroprevalence of COVID-19 IgG 100.0% 70.6% 100.0% 65.9% 0.256
Concentration of COVID-19 IgM (AU/ml) 8.17 27.9 (4.4, 145.6) 29.7 (8.6, 188.6) 25.5 (5.2152.7) 0.677
Seroprevalence of COVID-19 IgM 100.0% 73.5% 83.3% 75.6% 0.742
  1. Seroprevalence was defined as the proportion of patients with positive antibody results in the study
  2. P < 0.05 was considered a significant difference between groups